Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer

1980 ◽  
Vol 139 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Andrew L. Warshaw ◽  
Kang-Hyun Lee ◽  
William C. Wood ◽  
Alfred M. Cohen
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Serum Ribonuclease

scholarly journals Novel Cytological Diagnostic Scoring System for Pancreatic Specimens Obtained by Endoscopic Ultrasound-Guided Fine Needle Aspiration

2020 ◽  
Author(s):  
Yuri Kiso ◽  
Yoko Matsuda ◽  
Shikine Esaka ◽  
Yuri Hamashima ◽  
Hiroto Shirahata ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Fine Needle Aspiration ◽  
High Sensitivity ◽  
Needle Aspiration ◽  
Youden Index ◽  
Cytological Diagnosis ◽  
Benign Lesions ◽  
Ultrasound Guided ◽  
Fine Needle

Abstract Background: Cytological diagnosis of pancreatic specimens obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is often challenging because of the small amount of sample or well-differentiated adenocarcinoma with weak cytological atypia. Therefore, the sensitivity and specificity of cytological diagnosis for pancreatic cancer should be improved. Hence, we aimed to evaluate the indices, which are used to distinguish malignant from benign lesions for the cytological diagnosis of pancreatic EUS-FNA specimens. Methods: Seven reviewers, including 3 cytotechnologists and 4 medical doctors, evaluated 20 morphological indices in pancreatic specimens obtained by EUS-FNA (malignant, n=111; benign, n=31). Statistical analyses were performed using Fisher’s exact test, logistic regression analysis, area under the receiver operating characteristic curve, and Youden Index.Results: Among the 20 indices, there was a high incidence rate (>40%) of the following 13 indices in malignant cases: structural atypia, hyperchromatic nucleus, irregular cell polarity, unclear cell boundary, nuclear membrane thickening, anisonucleosis, overlapping, irregular nuclei, high nuclear/cytoplasmic ratio, binding decline, simultaneous appearance of malignant and benign cells, enlarged nucleoli, and background necrosis. When we diagnosed pancreatic specimens using these 13 cytological indices, the cutoff value of 8/9 showed the highest Youden index (0.950) as well as high sensitivity and specificity in distinguishing malignant from benign specimens (98% and 97%, respectively). Conclusion: Thirteen cytological indices showed high sensitivity and specificity in differentiating malignant and benign lesions using pancreatic EUS-FNA samples. Further validation or prospective studies are necessary to establish criteria for the cytological diagnosis of pancreatic cancer.

Low Sensitivity of the ki-ras Polymerase Chain Reaction for Diagnosing Pancreatic Cancer From Pancreatic Juice and Bile: A Multicenter Prospective Trial

2002 ◽  
Vol 20 (21) ◽  
pp. 4331-4337 ◽  
Author(s):  
Lorenz Trümper ◽  
Markus Menges ◽  
Heiner Daus ◽  
Daniel Köhler ◽  
Jan-Olaf Reinhard ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Polymerase Chain Reaction ◽  
Sensitivity And Specificity ◽  
Pancreatic Juice ◽  
Prospective Trial ◽  
Pcr Analysis ◽  
Duodenal Juice ◽  
Chain Reaction ◽  
Ras Gene ◽  
Polymerase Chain

PURPOSE: Early detection of pancreatic cancer using molecular markers may improve outcome. Mutations of the ki-ras oncogene are detected in 70% to 90% of pancreatic adenocarcinomas. A prospective, partially blinded, multicenter diagnostic trial was performed to test the sensitivity and specificity of the ki-ras polymerase chain reaction (PCR) analysis of pancreatic juice and bile specimens. PATIENTS AND METHODS: Specimens of pancreatic juice and bile were collected from 532 consecutive patients. Mutations in codon 12 of the ki-ras gene were identified by two independent enrichment PCRs and confirmed by direct sequencing. RESULTS: One hundred seventy-four of 532 patients were excluded from the final analysis (reasons: no amplifiable DNA, no specimen or only duodenal juice sent, lost to follow-up). Sixty-three of 358 patients had ductal pancreatic cancer. In 24 (38.1%) of 63 patients, a mutated ki-ras gene was identified in pancreatic juice and/or bile. Ki-ras mutations were found in four (8%) of 50 cases of chronic pancreatitis, in 10 (18.7%) of 53 cases of other malignancies of the pancreaticobiliary tree, and in 14 (7.3%) of 192 cases of benign diseases or normal findings. Sensitivity and specificity of the ki-ras PCR analysis for the detection of pancreatic cancer was 38.1% and 90.5%, respectively. CONCLUSION: In this prospective trial performed in nonselected patients, mutations of the ki-ras gene were detected in 38.1% of cases with pancreatic cancer. This test in its present form is not appropriate to confirm or screen for pancreatic cancer. More sensitive and/or quantitative PCR tests may improve the molecular diagnosis of pancreatic cancer.

scholarly journals Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Using Cell-Free DNA 5-Hydroxymethylation Signatures

2021 ◽  
Author(s):  
David Haan ◽  
Anna Bergamaschi ◽  
Gulfem Guler ◽  
Verena Friedl ◽  
Yuhong Ning ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Validation Dataset ◽  
Cell Free Dna ◽  
Independent Validation ◽  
Free Dna ◽  
Onset Diabetes ◽  
Increased Risk ◽  
New Onset

BACKGROUND Pancreatic cancer (PaC) has poor (10%) 5–year overall survival, largely due to predominant late-stage diagnosis. Patients with new-onset diabetes (NOD) are at a six– to eightfold increased risk for PaC. We developed a pancreatic cancer detection test for the use in a clinical setting that employs a logistic regression model based on 5–hydroxymethylcytosine (5hmC) profiling of cell-free DNA (cfDNA). METHODS: cfDNA was isolated from plasma from 89 subjects with PaC and 596 case–control non–cancer subjects, and 5hmC libraries were generated and sequenced. These data coupled with machine–learning, were used to generate a predictive model for PaC detection, which was independently validated on 79 subjects with PaC, 163 non–cancer subjects, and 506 patients with non–PaC cancers. RESULTS: The area under the receiver operating characteristic curve for PaC classification was 0.93 across the training data. Training sensitivity was 58.4% (95% confidence interval [CI]: 47.5–68.6) after setting a classification probability threshold that resulted in 98% (95% CI: 96.5–99) specificity. The independent validation dataset sensitivity and specificity were 51.9% (95% CI: 40.4–63.3) and 100.0% (95% CI: 97.8–100.0), respectively. Early–stage (stage I and II) PaC detection was 47.6% (95% CI: 23%–58%) and 39.4% (95% CI: 32%–64%) in the training and independent validation datasets, respectively. Sensitivity and specificity in NOD patients were 55.2% [95% CI: 35.7–73.6] and 98.4% [95% CI: 91.3–100.0], respectively. The PaC signal was identified in intraductal papillary mucinous neoplasm (64%), pancreatitis (56%), and non-PaC cancers (17%). CONCLUSIONS: The pancreatic cancer detection assay showed robust performance in the tested cohorts and carries the promise of becoming an essential clinical tool to enable early detection in high–risk NOD patients.

scholarly journals Serum CA 19-9 of Pancreatic Solid Mass Patients in Dr. Cipto Mangunkusumo National Central General Hospital

2020 ◽  
Vol 21 (3) ◽  
pp. 188-192
Author(s):  
Kaka Renaldi ◽  
Adelia Nova Prahasary ◽  
Muhammad Hamdan Yuwaafi ◽  
Muhammad Maulana
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
General Hospital ◽  
Sensitivity And Specificity ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Stadium Iv ◽  
Unresectable Tumor ◽  
Radiological Procedures

Background: Pancreatic cancer is a lethal disease associated with poor prognosis. CA 19-9 is one of the elevated tumor markers in pancreatic cancer. However, data regarding CA 19-9 serum levels in pancreatic cancer in Indonesia is still scarce. This study aims to evaluate the clinical use of CA 19-9 in pancreatic cancer patients in Dr. Cipto Mangunkusumo National Central General Hospital.Method: This study is a cross-sectional study that served data of demographic information, CA 19-9 level, TNM stage, site, histopathology, and resectability of pancreatic cancer. This study included 77 subjects. The data were collected from electronic medical records and registered data of patients in the Gastrointestinal Endoscopy Center, Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta between 2014 to 2019. Sensitivity and specificity analysis of CA 19-9 were performed using the ROC curve.Results: We found 77 pancreatic cancer patients with a mean age of 54.2+10.4 years old. Most of them were males (59,7%), were found at stadium IV (41,6%) and unresectable tumor (68,8%). Non-adenocarcinoma which was mainly found in the head of the pancreas (76,6%) were confirmed in 67,5% of patients. The sensitivity and specificity of CA-19 9 to diagnose adenocarcinoma pancreas were 32% and 62% (p=0.939).Conclusion: CA 19-9 should be used in aiding diagnosis, in conjunction with other modalities, such as radiological procedures and histopathology results. Measuring serum CA19-9 level in the early diagnosis could guide clinicians in determining the treatment and prognosis of pancreatic cancer.

Combined Evaluation of Serum Ribonuclease and Ferritin: Any Advantages in Pancreatic Cancer Diagnosis?

Oncology ◽  
1984 ◽  
Vol 41 (6) ◽  
pp. 393-395 ◽  
Author(s):  
C. Fabris ◽  
R. Farini ◽  
G.D. Del Favero ◽  
F. Grassi ◽  
D. Nitti ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis ◽  
Combined Evaluation ◽  
Serum Ribonuclease

scholarly journals An isozyme of serum ribonuclease specific for pancreatic cancer

1978 ◽  
Vol 74 (5) ◽  
pp. 1142 ◽  
Author(s):  
Ian G. Renner ◽  
Allan Mock ◽  
R. Reitherman ◽  
Adrian P. Douglas
Keyword(s):  
Pancreatic Cancer ◽  
Serum Ribonuclease

scholarly journals Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity

2014 ◽  
Vol 136 (11) ◽  
pp. 2616-2627 ◽  
Author(s):  
Bindhu Madhavan ◽  
Shijing Yue ◽  
Uwe Galli ◽  
Sanyukta Rana ◽  
Wolfgang Gross ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Cancer Diagnosis ◽  
Combined Evaluation

New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis

2006 ◽  
Vol 24 (2) ◽  
pp. 252-258 ◽  
Author(s):  
David V. Gold ◽  
David E. Modrak ◽  
Zhiliang Ying ◽  
Thomas M. Cardillo ◽  
Robert M. Sharkey ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Healthy Adult ◽  
Area Under The Curve ◽  
Positive Likelihood Ratio ◽  
High Sensitivity ◽  
Significant Difference ◽  
Acute And Chronic Pancreatitis ◽  
Pair Wise Comparison

Purpose To evaluate a new immunoassay for identification and quantitation of MUC1 in the sera of patients with pancreatic cancer or pancreatitis. The sensitivity and specificity of the assay are examined and compared to results from a CA19-9 immunoassay. Methods An in vitro enzyme immunoassay was established with monoclonal antibody PAM4 as the capture reagent, and a polyclonal anti-MUC1 antibody as the probe. Patient sera were obtained from healthy, adult patients with acute and chronic pancreatitis, and those with pancreatic and other forms of cancer, and were measured for PAM4-reactive MUC1. Results At a cutoff of 10.2 units/mL, 41 (77%) of 53 pancreatic cancer patients, none of the healthy individuals (n = 43), and only four (5%) of 87 patients with pancreatitis were positive above this value. Among nonpancreatic cancers investigated, colorectal cancers gave the highest percentage of positives (14%; five of 36). Overall, the sensitivity and specificity of the immunoassay for pancreatic cancer were 77% and 95%, respectively. Receiver operator characteristic analyses for discrimination of pancreatic cancer from pancreatitis provided an area under the curve of 0.89 (95% CI, 0.82 to 0.93), with a specificity of 95.4% and a positive likelihood ratio of 16.8. A direct pair-wise comparison of PAM4 and CA19-9 immunoassays for discrimination of pancreatic cancer and pancreatitis resulted in a significant difference (P < .003), with the PAM4 immunoassay demonstrating superior sensitivity and specificity. Conclusion The high sensitivity and specificity observed suggest that the PAM4-based immunoassay of circulating MUC1 may be useful in the diagnosis of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document